Precision BioSciences (DTIL) said Tuesday the US Food and Drug Administration granted Fast Track designation for PBGENE-HBV

gene editing therapy to cure chronic hepatitis B infection.

Precision said it is evaluating PBGENE-HBV in a global phase 1 trial, with data expected throughout 2025.

A drug granted the designation may be eligible for more frequent meetings with the FDA and rolling review for marketing approval, according to the company.

The shares were up more than 8% in recent trading.

Price: 4.83, Change: +0.37, Percent Change: +8.30